The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The safety of alloSCT following pembrolizumab treatment in R/R HL
In this video, John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, discusses a study evaluating the safety of allogeneic stem cell transplant (alloSCT) after pembrolizumab treatment in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). The final safety analysis showed that this approach can be safe, with manageable graft-versus-host disease (GvHD) in the acute setting, and that immune checkpoint blockade remains crucial for disease control even after alloSCT. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Hodgkin’s lymphoma has been a very interesting field where checkpoint inhibition has really changed the standard of care and has moved into the frontline setting given recent data from S1826. When we think about relapsed/refractory disease, again our gold standard drugs have been checkpoint inhibitors for the past few years and the question about the role of allogeneic stem cell transplant remains an important one...
Hodgkin’s lymphoma has been a very interesting field where checkpoint inhibition has really changed the standard of care and has moved into the frontline setting given recent data from S1826. When we think about relapsed/refractory disease, again our gold standard drugs have been checkpoint inhibitors for the past few years and the question about the role of allogeneic stem cell transplant remains an important one. We’ve presented the final safety data of the dataset where patients had received pembrolizumab and then might go on to receive an allogeneic stem cell transplant. In general, these data show that this approach can be safe. You may see a little bit more graft-versus-host disease potentially in the acute setting as well, but this is typically well managed and does not lead to excess treatment-related mortality. On the plus side, what we really see are much more favorable efficacy results in terms of disease control, again suggesting that immune checkpoint blockade has a very important role even when receiving adoptive T-cell therapy like allogeneic transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
